US20110318412A1 - Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia - Google Patents

Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia Download PDF

Info

Publication number
US20110318412A1
US20110318412A1 US12/301,223 US30122307A US2011318412A1 US 20110318412 A1 US20110318412 A1 US 20110318412A1 US 30122307 A US30122307 A US 30122307A US 2011318412 A1 US2011318412 A1 US 2011318412A1
Authority
US
United States
Prior art keywords
doxepin
canceled
composition
orally disintegrating
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/301,223
Other languages
English (en)
Inventor
Luigi Schioppi
Brian T. Dorsey
Michael Skinner
John Carter
Terry Cobb
Neil B. Kavey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIDCAP FUNDING IV LLC
PROCOM ONE Inc
Currax Pharmaceuticals LLC
Original Assignee
Somaxon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/301,223 priority Critical patent/US20110318412A1/en
Application filed by Somaxon Pharmaceuticals Inc filed Critical Somaxon Pharmaceuticals Inc
Assigned to PROCOM ONE, INC. reassignment PROCOM ONE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAVEY, NEIL B., COBB, TERRY
Assigned to SOMAXON PHARMACEUTICALS, INC. reassignment SOMAXON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHIOPPI, LUIGI, CARTER, JOHN, DORSEY, BRIAN, SKINNER, MICHAEL
Publication of US20110318412A1 publication Critical patent/US20110318412A1/en
Assigned to MIDCAP FINANCIAL, LLC reassignment MIDCAP FINANCIAL, LLC SECURITY AGREEMENT Assignors: PERNIX SLEEP, INC.
Assigned to MIDCAP FUNDING IV, LLC reassignment MIDCAP FUNDING IV, LLC PATENT TRANSFER AND ASSIGNMENT Assignors: MIDCAP FINANCIAL, LLC
Assigned to MIDCAP FINANCIAL, LLC reassignment MIDCAP FINANCIAL, LLC PATENT TRANSFER AND ASSIGNMENT Assignors: MIDCAP FUNDING V, LLC
Assigned to PERNIX THERAPEUTICS HOLDINGS, INC. reassignment PERNIX THERAPEUTICS HOLDINGS, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: SOMAXON PHARMACEUTICALS, INC.
Assigned to PERNIX SLEEP, INC. reassignment PERNIX SLEEP, INC. RELEASE OF SECURITY INTEREST IN PATENT RIGHTS REEL/FRAME 030441/0229 Assignors: MIDCAP FUNDING IV, LLC (SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL, LLC)
Assigned to PERNIX SLEEP, INC. reassignment PERNIX SLEEP, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERNIX THERAPEUTICS HOLDINGS, INC.
Assigned to CURRAX PHARMACEUTICALS LLC reassignment CURRAX PHARMACEUTICALS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERNIX SLEEP, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • Embodiments of the invention disclosed herein relate to low-dose, oral, transmucosal doxepin pharmaceutical formulations, including buccal, sublingual, and fastmelt formulations, methods of making the formulations, and the use of these formulations to promote sleep.
  • insomnia sleep disorders
  • Sleep is essential for health and quality of life.
  • Insomnia is a growing health problem in the United States. It is believed that more than 10-15 million people suffer from chronic insomnia and up to an additional 70 million people suffer from some form of insomnia each year.
  • Insomnia is a condition characterized by difficulty falling asleep (sleep onset), waking frequently during the night (fragmented sleep), waking too early (premature final awakening), and/or waking up feeling un-refreshed.
  • hypnotic drugs There are numerous limitations of the currently available hypnotic drugs and there is no one drug that can address all three components of insomnia efficacy (onset, maintenance and duration) with a clean safety profile. Side effects of hypnotics include: residual sedation, lethargy, disorientation, impaired psychomotor function including light headedness and falls, amnesia, headaches, agitation, nightmares, dry mouth, metallic taste, complex sleep behaviors, dependence, withdrawal syndrome and rebound insomnia. The side effects are often worse in elderly patients. These drugs also may be subject to the additional problems of addictive potential and tolerance. The limitations of the currently available hypnotics are reflected in current medical guidelines that recommend and emphasize the use of non drug treatment options as first line therapy.
  • Embodiments of the invention provide low-dose, oral, transmucosal formulations of doxepin and doxepin compounds, and address the unique aspects of sleep disorders.
  • Embodiments of the invention disclosed herein relate to low-dose doxepin formulations, and methods of making and using the same.
  • some embodiments relate to oral, transmucosal formulations.
  • Transmucosal delivery offers the potential for once daily dosing of oral drugs and can avoid, at least in part, the effects of first pass metabolism.
  • doxepin dissolves quickly in the stomach, it undergoes a significant first pass extraction or metabolism in the liver. This first pass extraction can influence the impact of the therapeutic effect of the administered doxepin. For example, it can result in a delay in the onset of the sleep promoting action of the drug.
  • some embodiments relate to formulations that can be administered so as to be absorbed or taken up, at least in part, in the mouth and/or intestines.
  • the dosage form can be uniform with respect to drug substance content, fast dissolving, stable, palatable, and otherwise acceptable to patients in order to maximize patient compliance.
  • early and/or accelerated onset of drug action also can be advantageous.
  • early onset of drug action can be important due to the discreet window of time in which a patient needs to sleep.
  • the dosage form preferably maintains sleep for a full 7 or 8 hour sleep cycle without significant next-day sedation.
  • the selected dosage level of a drug to be administered to a patient can depend upon, for example, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. It will be understood, however, that the specific dose level for any particular patient can depend upon a variety of factors including the genetic makeup, body weight, general health, diet, time and route of administration, combination with other drugs and the particular condition being treated, and its severity. For the treatment of insomnia, preferably one dose is administered prior to bedtime.
  • the selected dosage can also be determined by targeting a mean plasma concentration profile that has been associated with improvement in one or more polysomnography sleep variables including latency to persistent sleep, wake after sleep onset, total sleep time, sleep efficiency, wake time during sleep, or wake time after sleep. Due to the limited time frame for the treatment of insomnia, drug formulations that achieve an effective plasma concentration are desirable.
  • the clinically effective drug plasma concentration and duration of said drug plasma concentration may be achieved by any suitable route of administration including oral, buccal, sublingual, transmucosal, or intestinal using any suitable formulation.
  • insomnia it can be desirable to have a blood plasma concentration of drug in a therapeutically effective range as rapid as possible for example, to induce sleep onset as quickly as possible. Additionally, it can be desirable to have the dose of drug in the plasma be maintained through the sleep period to maintain the beneficial effects on other sleep parameters, such as awakenings after sleep onset and sleep duration.
  • a patient with insomnia can be treated with an orally disintegrating formulation of doxepin, pharmaceutically acceptable salts, or other doxepin-related compounds that can be partially or substantially absorbed in the oral mucosa to afford a therapeutic blood plasma level that can be maintained through the sleep period.
  • the orally disintegrating formulation of doxepin, pharmaceutically acceptable salts, or other doxepin-related compounds when taken by a patient can afford a therapeutically effective blood plasma concentration within 60 minutes and be maintained at a therapeutically relevant level throughout the sleep period.
  • the orally disintegrating formulation of doxepin, pharmaceutically acceptable salts, or other doxepin-related compounds when taken by a patient can afford a therapeutically effective blood plasma concentration within 40 minutes and be maintained at a therapeutically relevant level throughout the sleep period. In some embodiments, the orally disintegrating formulation of doxepin, pharmaceutically acceptable salts, or other doxepin-related compounds when taken by a patient can afford a therapeutically effective blood plasma concentration of doxepin within 20 minutes and be maintained at a therapeutically relevant level throughout the sleep period.
  • the doxepin, pharmaceutically acceptable salts, or other doxepin-related compounds that is absorbed through the oral mucosa can afford a rapid elevation of drug in the blood plasma to above the therapeutic level that lessens, although still being maintained above the therapeutic level, and then slowly rising as additional drug is absorbed intestinally.
  • substantially all of the doxepin can be absorbed through the oral mucosa affording a rapid elevation of drug in the blood plasma to above the therapeutic level that is maintained above the therapeutic level throughout the sleep period.
  • some embodiments relate to manufacturing processes for the formulations, as well as methods of using the formulations.
  • the formulations have one or more desirable physical properties, have preferable functional characteristics, and/or permit efficient and economical manufacturing of low-dose, oral, transmucosal doxepin dosage forms.
  • the active ingredient and excipients preferably have suitable flow properties to ensure efficient mixing and acceptable content uniformity, weight uniformity, potency, disintegration, dissolution, hardness, and friability of the final dosage form.
  • Good flow properties also may be beneficial for precise volumetric feeding of the material to a die cavity.
  • efficient mixing and acceptable content uniformity are difficult to achieve for low dose dosage forms.
  • Mixed particle sized powders can segregate due to operational vibrations and/or fluidization resulting in final dosage forms with poor drug or active pharmaceutical ingredient (API) content uniformity.
  • Active substances with a small particle size mixed with excipients having a larger particle size will typically segregate or de-mix during the formulation process.
  • the problem of small particle size and poor flowability can be addressed by enlarging the particle size of the active substance, usually by granulation of the active ingredient either alone or in combination with a filler and/or other conventional excipients.
  • embodiments of the invention disclosed herein address and achieve one or more of the above-mentioned considerations. Some embodiments surprisingly achieve several or many of the considerations.
  • embodiments disclosed herein relate to oral, transmucosal dosage forms comprising low doses of doxepin hydrochloride, methods of manufacturing these dosage forms, and methods of using the formulations and dosage forms.
  • the low doses of doxepin hydrochloride can be provided as rapidly disintegrating dosage forms, as described herein, that can be advantageously used for treatment of insomnia.
  • the formulations have one or more of improved friability, compression, dissolution, uniformity, disintegration, palatability, and the like.
  • the formulations can permit at least one or more of rapid onset, greater and/or more rapid plasma levels, and the like.
  • the formulations can result in more rapid drug action (e.g., sleep onset) without otherwise significantly changing the pharmacokinetic profile of low dose doxepin seen with other formulations.
  • Some embodiments provide a method for treating insomnia comprising administering to a patient an oral-mucosal low dose of doxepin, a pharmaceutically acceptable salt thereof, or doxepin-related compounds.
  • the administered substance can be delivered, for example, in a daily dosage ranging from about 0.01 to about 10 milligrams.
  • the daily dosage can range, for example, from about 0.5 to about 9 milligrams, from about 1 to about 9 milligrams, from about 1 to about 6 milligrams, from about 1 to about 3 milligrams, from about 2 to about 3 milligrams, or the like.
  • the pharmaceutically acceptable salt can be any salt, including for example the hydrochloride salt.
  • the prodrug can be any prodrug.
  • Some embodiments relate to treating insomnia comprising administering to a patient doxepin, a pharmaceutically acceptable salt thereof, or doxepin-related compounds, in an orally disintegrating dosage form that can be substantially absorbed across the oral mucosa to avoid, at least in part, intestinal absorption and first pass metabolism.
  • a patient doxepin, a pharmaceutically acceptable salt thereof, or doxepin-related compounds in an orally disintegrating dosage form that can be substantially absorbed across the oral mucosa to avoid, at least in part, intestinal absorption and first pass metabolism.
  • between about 1% and 99%, or between about 5% and 95%, or between about 10% and 90% of the doxepin, or pharmaceutically acceptable salts, or other doxepin-related compounds can be absorbed across the oral mucosa thereby avoiding intestinal absorption and first pass metabolism.
  • greater than 80% of the doxepin, or pharmaceutically acceptable salts, or other doxepin-related compounds, thereof can be absorbed across the oral mucosa thereby avoiding intestinal absorption and first pass metabolism.
  • greater than 60% of the doxepin, or pharmaceutically acceptable salts, or other doxepin-related compounds can be absorbed across the oral mucosa thereby avoiding intestinal absorption and first pass metabolism.
  • greater than 40% of the doxepin, or pharmaceutically acceptable salts thereof, or other doxepin-related compounds can be absorbed across the oral mucosa thereby avoiding intestinal absorption and first pass metabolism.
  • greater than 20% of the doxepin, or pharmaceutically acceptable salts thereof, or other doxepin-related compounds can be absorbed across the oral mucosa thereby avoiding intestinal absorption and first pass metabolism.
  • the doxepin that is not absorbed across the oral mucosa can be absorbed intestinally following the normal pharmacokinetics for this drug.
  • Preferred embodiments provide a method for treating insomnia comprising administering to a patient doxepin, a pharmaceutically acceptable salt thereof, or doxepin-related compounds in an orally disintegrating formulation where the blood plasma level of doxepin reaches a therapeutic level within 60 minutes of administration. Further, in some embodiments, a therapeutically effective blood plasma level is achieved within 40 minutes of administration of doxepin, or a pharmaceutically acceptable salt thereof. In a preferred embodiment, a therapeutically effective blood plasma level is achieved within 20 minutes of administration of doxepin, or a pharmaceutically acceptable salt thereof.
  • Preferred embodiments provide methods of treating sleep onset insomnia, comprising administering to a patient doxepin, a pharmaceutically acceptable salt thereof, or doxepin-related compounds thereof in an orally disintegrating formulation where the blood plasma level of doxepin reaches a therapeutic level within 60 minutes of administration. Further, in some embodiments, a therapeutic blood plasma level of doxepin is achieved within 40 minutes of administration of doxepin, or a pharmaceutically acceptable salt thereof. In a preferred embodiment, a therapeutic blood plasma level of doxepin is achieved within 20 minutes of administration of doxepin, or a pharmaceutically acceptable salt thereof.
  • an orally disintegrating formulation of about 6 mg of doxepin, or pharmaceutically acceptable salts, or other doxepin-related compounds can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 60 minutes.
  • “Substantially dissolved” as used herein can mean that approximately 1% to about 99%, 1% to about 75%, or 1% to about 50% of the formulation can be dissolved within the specified time frame.
  • the orally disintegrating formulation can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 40 minutes.
  • the orally disintegrating formulation can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 20 minutes.
  • an orally disintegrating formulation of about 3 mg of doxepin, pharmaceutically acceptable salts thereof, or other doxepin-related compounds can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 60 minutes. In some aspects, the orally disintegrating formulation can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 40 minutes. In some aspects, the orally disintegrating formulation can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 20 minutes.
  • an orally disintegrating formulation of about 1 mg of doxepin, pharmaceutically acceptable salts thereof, or other doxepin-related compounds can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 60 minutes. In some aspects, the orally disintegrating formulation can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 40 min. In some aspects, the orally disintegrating formulation can be substantially dissolved within 5 minutes and a therapeutically effective plasma concentration of doxepin achieved within 20 minutes.
  • an orally disintegrating formulation of about 6 mg of doxepin, a pharmaceutically acceptable salt thereof can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 60 minutes. In some aspects, the orally disintegrating formulation can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 40 minutes. In some aspects, the orally disintegrating formulation can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 20 minutes.
  • an orally disintegrating formulation of 3 mg of doxepin, a pharmaceutically acceptable salt thereof can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 60 minutes. In some aspects, the orally disintegrating formulation can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 40 minutes. In some aspects, the orally disintegrating formulation can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 20 minutes.
  • an orally disintegrating formulation of 1 mg of doxepin, a pharmaceutically acceptable salt thereof can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 60 minutes. In some aspects, the orally disintegrating formulation can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 40 minutes. In some aspects, the orally disintegrating formulation can be substantially disintegrated within 60 seconds and a therapeutically effective plasma concentration of doxepin achieved within 20 minutes.
  • the doxepin, or a pharmaceutically acceptable salt thereof can be formulated in a rapidly orally disintegrating dosage form so that between about 1% and 99%, or between about 5% and 95%, or between about 10% and 90% of the doxepin is absorbed across the oral mucosa.
  • the doxepin or a pharmaceutically acceptable salt thereof can be formulated in a rapidly orally disintegrating dosage form so that greater than 70% of the doxepin is absorbed across the oral mucosa.
  • the doxepin or a pharmaceutically acceptable salt thereof can be formulated in a rapidly orally disintegrating dosage form so that greater than 50% of the doxepin is absorbed across the oral mucosa.
  • the doxepin, or a pharmaceutically acceptable salt thereof can be formulated in a rapidly orally disintegrating dosage form so that greater than 30% of the doxepin is absorbed across the oral mucosa. In some embodiments, the doxepin, or a pharmaceutically acceptable salt thereof can be formulated in a rapidly orally disintegrating dosage form so that greater than 10% of the doxepin is absorbed across the oral mucosa.
  • the insomnia can be a chronic insomnia or a non-chronic insomnia.
  • chronic (e.g., greater than 3-4 weeks) or non-chronic insomnias a patient may suffer from difficulties in sleep onset, sleep maintenance (interruption of sleep during the night by periods of wakefulness), sleep duration, sleep efficiency, premature early-morning awakening, or a combination thereof.
  • the insomnia may be attributable to the concurrent use of other medication, for example.
  • the non-chronic insomnia can be, for example, a short term insomnia or a transient insomnia.
  • the chronic or non-chronic insomnia can be a primary insomnia or an insomnia that is secondary to another condition, for example a disease such as depression or chronic fatigue syndrome.
  • the patient can be one that is not suffering from an insomnia that is a component of a disease, or a patient can be treated that is otherwise healthy.
  • the chronic or non-chronic insomnia can be a primary insomnia, that is, one that is not attributable to another mental disorder, a general medical condition, or a substance. In many cases, such conditions may be associated with a chronic insomnia and can include, but are not limited to, insomnia attributable to a diagnosable DSM-IV disorder, a disorder such as anxiety or depression, or a disturbance of the physiological sleep-wake system.
  • the insomnia can be non-chronic, or of short duration (e.g., less than 3-4 weeks).
  • insomnia examples of causes of such insomnia may be extrinsic or intrinsic and include, but are not limited to environmental sleep disorders as defined by the International Classification of Sleep Disorders (ICSD) such as inadequate sleep hygiene, altitude insomnia or adjustment sleep disorder (e.g., bereavement). Also, short-term insomnia may also be caused by disturbances such as shift-work sleep disorder.
  • ISD International Classification of Sleep Disorders
  • sleep disorders such as inadequate sleep hygiene, altitude insomnia or adjustment sleep disorder (e.g., bereavement).
  • short-term insomnia may also be caused by disturbances such as shift-work sleep disorder.
  • compositions that includes doxepin, pharmaceutically acceptable salts thereof, and/or other doxepin-related compounds.
  • such composition of doxepin or a pharmaceutically acceptable salt thereof can be provided in a daily dosage and/or unit dosage ranging from about 0.01 to about 10 milligrams.
  • the pharmaceutically acceptable salt of doxepin can be a hydrohalic acid salt.
  • the pharmaceutically acceptable salt of doxepin can be the hydrochloride salt.
  • Embodiments of the invention disclosed herein relate to buccal, sublingual and fastmelt low-dose doxepin formulations. Also, some embodiments relate to manufacturing processes for the formulations, as well as methods of using the formulations. In some aspects the formulations have one or more desirable physical properties, have preferable functional characteristics, and/or permit efficient and economical manufacturing of low dose doxepin dosage forms.
  • Embodiments of the invention provide orally disintegrating low dose formulations of doxepin and doxepin compounds, and also addresses and overcomes the challenges and problems associated with formulating and manufacturing orally disintegrating low-dose doxepin dosage forms. Additionally, embodiments of the invention provide that doxepin, pharmaceutically acceptable salts thereof, or other doxepin-related compounds can be substantially absorbed across the oral mucosa to afford a therapeutically effective plasma concentration of doxepin concentration within 60 minutes of treatment.
  • Additional embodiments disclosed herein relate to methods of manufacture for low-dose dosage forms of doxepin, including, for example, on a large scale.
  • the methods of manufacture can achieve uniformity of drug substance content and overcome segregation issues that can plague low dose formulations, and can do so in an economic and efficient manner.
  • Some embodiments of the invention relate to low dose doxepin formulations that are amenable to direct compression and that produce a high yield of buccal, sublingual and/or fastmelt low-dose doxepin dosage forms having acceptable content uniformity, and hardness, and friability.
  • said fast disintegrating doxepin is an orally disintegrating tablet (ODT).
  • ODT is formulated with doxepin HCl. It is not intended that the invention be limited to any specific dosage of doxepin in a given dosage form. However, in a preferred embodiment, the dosage of doxepin, per ODT, is in the range between 1 mg and 9 mg. Further, in a more preferred embodiment, the dosage of doxepin, per ODT, is 1 mg or 3 mg or 6 mg.
  • the invention also relates to methods for the administration of fast disintegrating, oral, transmucosal formulations of doxepin which rapidly exert a therapeutic effect to treat sleep onset, for example, buccal, sub-lingual and ODT formulations. While it is not intended the invention be limited to any specific formulation, in a preferred embodiment, said fast disintegrating formulation is an ODT (Orally Disintegrating Tablet).
  • ODT Orally Disintegrating Tablet
  • a pharmaceutical composition that can comprise from about 0.1 to about 9 mg of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, and from about 15% to about 99.9% w/w of at least one quick dissolve delivery system or at least one directly compressible excipient for orally disintegrating formulations.
  • the orally disintegrating composition substantially disintegrates and partially dissolves in the oral cavity.
  • composition that can comprise from about 0.1 to about 9 mg of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, and from about 50% to about 90% w/w Pharmaburst, or other similar specialty excipient.
  • Pharmaburst is a specialty excipient designed specifically for ODT applications supplied by SPI Pharma.
  • the composition can further comprise doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in an amount of about 1 mg to about 9 mg.
  • doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof can be provided in an amount of about 3 mg.
  • doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof can be provided in an amount of about 6 mg.
  • the pharmaceutical composition can contain from about 60% to about 85% w/w Pharmaburst.
  • the pharmaceutical composition can contain from about 70% to about 80% w/w Pharmaburst.
  • the amount of Pharmaburst in the pharmaceutical composition can be 50%, 60%, 70% 75%, 80%, 81%, 82%, 83%, 84%, 85% w/w.
  • the pharmaceutical composition can contain Pharmaburst in an amount of about 83% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in an amount of about 6 mg.
  • the pharmaceutical composition can contain Pharmaburst in an amount of about 83% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in an amount of about 3 mg.
  • the pharmaceutical composition can contain Pharmaburst in an amount of about 83% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in an amount of about 1 mg.
  • the pharmaceutical composition can be a tablet, a lozenge, a chewing gum, a film, a capsule, a gel cap, a caplet, a pellet, or a bead.
  • the pharmaceutical compositions disclosed herein comprise from about 0.1 to about 9 mg of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, and from about 15% to about 30% w/w RxCIPIENTSTTM FM1000.
  • RxCIPIENTSTTM FM1000 is a specialty excipient designed specifically for ODT applications comprised of calcium silicate, supplied by Huber.
  • the pharmaceutical compositions contain from about 18% to about 27% w/w RxCIPIENTSTTM FM1000.
  • the pharmaceutical compositions contain from about 20% to about 25% w/w RxCIPIENTSTM FM1000.
  • the pharmaceutical composition can contain RxCIPIENTSTTM FM1000 in an amount of about 20-30% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug or metabolite thereof in an amount of about 1 mg.
  • the pharmaceutical composition can contain RxCIPIENTSTTM FM1000 in an amount of about 20-30% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, in an amount of about 6 mg.
  • the pharmaceutical composition can contain RxCIPIENTSTM FM1000 in an amount of about 20-30% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, in an amount of about 3 mg.
  • RxCIPIENTSTTM FM1000 is used in combination with another excipient such as mannitol, microcrystalline cellulose, dicalcium phosphate, and the like.
  • the pharmaceutical composition can be a tablet, a lozenge, a chewing gum, a film, a capsule, a gel cap, a caplet, a pellet, or a bead.
  • compositions disclosed herein can comprise from about 0.1 to about 9 mg of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, and from about 25% to about 60% w/w F-MeltTM Type M or F-MeltTM Type C.
  • F-MeltTM is a specialty excipient designed specifically for ODT applications supplied by Fuji Chemicals of Japan.
  • the pharmaceutical composition can contain from about 30% to about 55% w/w F-MeltTM.
  • the pharmaceutical composition can contain from about 40% to about 50% w/w F-MeltTM.
  • the amount of F-MeltTM in the pharmaceutical composition can be about 58% w/w.
  • the pharmaceutical composition can contain F-MeltTM an amount of about 58% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in an amount of about 6 mg.
  • the pharmaceutical composition can contain F-MeltTM in an amount of about 58% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, in an amount of about 3 mg.
  • the pharmaceutical composition can contain F-MeltTM in an amount of about 58% w/w and doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in an amount of about 1 mg.
  • the pharmaceutical composition can be a tablet, a chewing gum, a lozenge, a film, a capsule, a gel cap, a caplet, a pellet, or a bead.
  • the composition can be in the form of a tablet, a lozenge, a chewing gum, a capsule, a gel cap, a caplet, a pellet, a bead, or the like, where the composition can have a total mass of about 50 mg to about 300 mg. In a preferred embodiment the composition can have a mass of from about 75 mg to about 100 mg. In some embodiments, the composition can have a total mass of 50 mg, 75 mg, 80 mg, 90 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, or 300 mg.
  • the pharmaceutical composition can comprise from about 0.1 to about 9 mg of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, and at least one excipient.
  • the excipient can be selected from, for example, but not limited to, RxCIPIENTSTTM FM1000, Pharmaburst, F-MeltTM, silicified microcrystalline cellulose, microcrystalline cellulose, lactose, a compressible sugar, xylitol, sorbitol, mannitol, such as Perlitol 200 SD, pregelatinized starch, maltodextrin, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate DC, a calcium silicate, and the like.
  • the pharmaceutical composition can be comprised from about 0.1 to about 9 mg of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, and Perlitol 200 SD.
  • the Perlitol 200 SD can be provided in amount of about 20% to about 85% w/w.
  • the Perlitol 200 SD can be provided in amount of about 15% to about 45% w/w. In a further preferred aspect, 45% to about 75% w/w.
  • the pharmaceutical composition can further include an additional excipient, for example, silicified microcrystalline cellulose, microcrystalline cellulose, lactose, compressible sugars, xylitol, sorbitol, mannitol, pregelatinized starch, maltodextrin, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate DC, and the like.
  • an additional excipient for example, silicified microcrystalline cellulose, microcrystalline cellulose, lactose, compressible sugars, xylitol, sorbitol, mannitol, pregelatinized starch, maltodextrin, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate DC, and the like.
  • the pharmaceutical can include a glidant.
  • the glidant can be colloidal silicon dioxide and the like.
  • the colloidal silicon dioxide can be provided in an amount of about 0.1 to about 6.0% w/w. In a preferred embodiment, the colloidal silicon dioxide can be provided in an amount of about 0.1 to about 1.5% w/w.
  • the composition can include a lubricant, for example, magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil, glyceryl behenate, polyethylene glycol and the like.
  • a lubricant for example, magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil, glyceryl behenate, polyethylene glycol and the like.
  • the lubricant can be sodium stearyl fumarate.
  • the sodium stearyl fumarate can be provided in an amount of about 0.25 to about 2.0% w/w.
  • the composition can include a disintegrant or a supplemental binder.
  • the disintegrant can be, in some embodiments, croscarmellose sodium, sodium starch glycolate, crospovidone, microcrystalline cellulose, pregelatinized starch, corn starch, alginic acid, ion exchange resin and the like.
  • the pharmaceutical composition can contain a “superdisintegrant,” such as, Crospovidone XL, Ac-Di-Sol” (Croscarmellose Sodium) or “Explotab” (Sodium Starch Glycolate), or the like, in an amount of about 1% to about 10% w/w.
  • the supplemental binder can be hydroxypropyl cellulose, polyvinylpyrrolidone, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, sodium carboxy methylcellulose, and the like.
  • the formulations disclosed herein can also comprise artificial or natural sweeteners, flavors, flavor enhancers and colorants.
  • sweeteners and/or flavors can be included to mask the taste of the drug substance.
  • Exemplary sweeteners include, for example, Aspartame, Sodium Saccharin, Sodium Cyclamate, Aceulfame K Sucralose, and the like.
  • one or more colorants can be used to compliment the selected flavor (for example, pink for cherry, etc.).
  • compositions disclosed herein can be in the form of tablets, chewing gums, lozenges, films, capsules, gel caps, caplets, pellets, beads, or the like.
  • Doxepin can be provided in an amount of about 1 to about 2 mg. In one embodiment, doxepin can be provided in an amount of about 1 mg. In another embodiment, doxepin is provided in an amount of about 3 to about 4 mg. In another aspect, doxepin can be provided in an amount of about 3 mg. In another embodiment, doxepin can be provided in an amount of about 6 to about 7 mg. In one aspect of this embodiment, doxepin can be provided in an amount of about 6 mg. In still another aspect of the embodiment, doxepin can be provided in an amount of about 8 to about 9 mg.
  • Embodiments of the invention also provide compositions comprising from about 0.5 to about 9 mg doxepin having hardness values of at least 2 Kp. In other embodiments, the compositions have hardness values of at least 4 Kp, or at least 6 Kp or higher. Some embodiments can provide a tablet that can be comprised of from about 0.5 to about 9 mg doxepin that can have a friability value of 1% or less. In other embodiments, the tablet can have a friability value of about 0.75%, of about 0.5% or of about 0.25%.
  • Embodiments of the invention also provide pharmaceutical compositions that can be comprised of from about 0.5 to about 9 mg doxepin that can have disintegration times of less than 1 minute per USP protocols.
  • the compositions can have disintegration time of less than 30 seconds, of less than 20 seconds, of less than 10 seconds or of less than 6 seconds.
  • compositions comprising from about 0.1 to about 9 mg doxepin having at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in 0.1 N HCl or Simulated Gastric Fluid USP without enzymes.
  • USP U.S. Pharmacopeia
  • the composition has at least an 85 percent release rate at 15 minutes, at least an 85 percent release rate at 10 minutes, at least an 85 percent release rate at 5 minutes, at least a 90 percent release rate at 30 minutes, at least a 95 percent release rate at 30 minutes.
  • the compositions also have at least an 85 percent release of doxepin within 30 minutes using U.S.
  • USP Pharmacopeia
  • USP Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 4.5 buffer and/or at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 6.8 buffer of Simulated Intestinal Fluid USP without enzymes.
  • compositions comprising from about 0.5 to about 9 mg doxepin having at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 4.5 buffer.
  • USP U.S. Pharmacopeia
  • the compositions have at least an 85 percent release rate at 15 minutes, at least an 85 percent release rate at 10 minutes, at least an 85 percent release rate at 5 minutes, at least a 90 percent release rate at 30 minutes or at least a 95 percent release rate at 30 minutes.
  • compositions comprising from about 0.5 to about 9 mg doxepin having at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 6.8 buffer or Simulated Intestinal Fluid USP without enzymes.
  • USP U.S. Pharmacopeia
  • Embodiments of the invention also provide pharmaceutical compositions comprising about 0.5 to about 9 mg doxepin having two or more of the following characteristics: a hardness value of at least 2 Kp, a friability value of 1% or less, a disintegration time of less than 1 minute as per USP protocols, at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in 0.1 N HCl or Simulated Gastric Fluid USP without enzymes, at least an 85 percent release of doxepin within 30 minutes using U.S.
  • USP U.S. Pharmacopeia
  • USP Pharmacopeia
  • USP Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 4.5 buffer, and at least an 85 percent release of doxepin within 30 minutes using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a pH 6.8 buffer or Simulated Intestinal Fluid USP without enzymes.
  • Another embodiment provides a batch of unit dosage forms, each comprising from about 0.5 to about 9 mg doxepin, and the batch having content uniformity values between about 85% to 115% of label claim.
  • the batch of unit dosage forms has content uniformity values of between about 90% to 110% of label claim or of between about 95% to 105% of label claim.
  • the batch of unit dosage forms comprises from about 100,000 to about 10,000,000 units, from about 500,000 to about 5,000,000 units, from about 1,000,000 to about 4,000,000 units, or from about 3,000,000 to about 4,000,000 units.
  • the units can be in the form of tablets, chewing gums, lozenge, films, capsules, caplets, pills, gel caps, pellets, beads, and the likes
  • Embodiments of the invention also provides a batch of unit dosage forms, each comprising from about 0.5 to about 9 mg doxepin, having a content uniformity percent relative standard deviation of less than 5%.
  • the batch of unit dosage forms has a content uniformity percent relative standard deviation of less than 4%, less than 3%, less than 2% or less than 1%.
  • Embodiments of the invention also provide methods of making a plurality of doxepin unit dosage forms.
  • the methods can include, for example, providing an amount of doxepin to obtain a plurality of doxepin tablets, wherein each tablet comprises between about 0.1 mg to 9 mg of doxepin; providing one or more excipients; mixing said doxepin and excipients such that the plurality of doxepin dosage forms comprises at least one of content uniformity values between about 85% and 115% of label claim or a content uniformity percent relative standard deviation of less than 5%.
  • the plurality of dosage forms comprises content uniformity values between about 90% to 110% of label claim, or between about 95% to 105% of label claim.
  • the plurality of dosage forms comprises a content uniformity percent relative standard deviation of less than 5%, of less than 4%, of less than 3%, of less than 2%, or of less than 1%.
  • at least one excipient can be quick dissolve delivery system, such as, for example, a RxCIPIENTSTTM FM 1000, Pharmaburst, F-MeltTM, and the like.
  • a second excipient can be selected from the group consisting of microcrystalline cellulose, lactose, a compressible sugar, xylitol, sorbitol, mannitol, pregelatinized starch, maltodextrin, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate DC, a calcium silicate, and the like.
  • the invention can provide methods of making a plurality of doxepin unit dosage forms, wherein doxepin is combined with RxCIPIENTSTM FM1000.
  • the RxCIPIENTSTM FM1000 is provided in an amount of about between about 15% and 30% w/w.
  • the plurality of dosage forms can include from about 100,000 to about 10,000,000 units, from about 500,000 to about 5,000,000 units, from about 1,000,000 to about 4,000,000 units or from about 3,000,000 to about 4,000,000 units.
  • the invention can provide methods of making a plurality of doxepin unit dosage forms, wherein doxepin is combined with Pharmaburst.
  • the Pharmaburst is provided in an amount of between about 50 and about 90% w/w.
  • the invention can provide methods of making a plurality of doxepin unit dosage forms, wherein doxepin is combined with F-MeltTM.
  • the F-MeltTM can be provided in an amount of about 25% to about 65% w/w.
  • the plurality of dosage forms can include from about 100,000 to about 10,000,000 units, from about 500,000 to about 5,000,000 units, from about 1,000,000 to about 4,000,000 units or from about 3,000,000 to about 4,000,000 units.
  • a pharmaceutical unit dosage form that can be comprised of doxepin or a pharmaceutically-acceptable salt thereof in an amount equivalent to about 9 mg doxepin hydrochloride; one or more pharmaceutically-acceptable excipients; and optionally, a capsule or coating.
  • the excipients and any capsule or coating can be selected to provide a rapid orally disintegrating unit dosage form that is at least externally solid and that has dissolution and bioavailability characteristics such that after administration to a 70 kg human, the dosage form can provide a therapeutically effective plasma concentration of doxepin within a time frame of not more than about 60 minutes.
  • the dosage form can be a tablet, a chewing gum, a lozenge, a film, a capsule, a pill, a caplet, a gel cap, a pellet, a bead, or a dragee.
  • the dosage form can be an orally disintegrating tablet.
  • the dosage form can be a capsule.
  • the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 40 minutes. In yet another embodiment, the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 20 minutes.
  • a pharmaceutical unit dosage form that can be comprised of doxepin or a pharmaceutically-acceptable salt thereof in an amount equivalent to about 6 mg doxepin hydrochloride; one or more pharmaceutically-acceptable excipients; and optionally, a capsule or coating.
  • the excipients and any capsule or coating can be selected to provide a rapid orally disintegrating unit dosage form that can be at least externally solid and that can have dissolution and bioavailability characteristics such that after administration to a 70 kg human, the dosage form can provide a therapeutically effective plasma concentration of doxepin within a time frame of not more than about 60 minutes.
  • the dosage form can be a tablet, a chewing gum, a lozenge, a film, a capsule, a pill, a caplet, a gel cap, a pellet, a bead, or a dragee.
  • the dosage form can be an orally disintegrating tablet.
  • the dosage form can be a capsule.
  • the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 40 minutes. In yet another embodiment, the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 20 minutes.
  • a pharmaceutical unit dosage form that can be comprised of doxepin or a pharmaceutically-acceptable salt thereof in an amount equivalent to about 3 mg doxepin hydrochloride; one or more pharmaceutically-acceptable excipients; and optionally, a capsule or coating.
  • the excipients and any capsule or coating can be selected to provide a rapid orally disintegrating unit dosage form that is at least externally solid and that has dissolution and bioavailability characteristics such that after administration to a 70 kg human, the dosage form can provide a therapeutically effective plasma concentration of doxepin within a time frame of not more than about 60 minutes.
  • the dosage form can be a tablet, a chewing gum, a lozenge, a film, a capsule, a pill, a caplet, a gel cap, a pellet, a bead, or a dragee.
  • the dosage form is an orally disintegrating tablet.
  • the dosage form can be a capsule.
  • the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 40 minutes. In yet another embodiment, the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 20 minutes.
  • a pharmaceutical unit dosage form that can comprise of doxepin or a pharmaceutically-acceptable salt thereof in an amount equivalent to about 1 mg doxepin hydrochloride; one or more pharmaceutically-acceptable excipients; and optionally, a capsule or coating.
  • the excipients and any capsule or coating can be selected to provide a rapid orally disintegrating unit dosage form that is at least externally solid and that has dissolution and bioavailability characteristics such that after administration to a 70 kg human, the dosage form can provide a therapeutically effective plasma concentration of doxepin within a time frame of not more than about 60 minutes.
  • the dosage form can be a tablet, a chewing gum, a lozenge, a film, a capsule, a pill, a caplet, a gel cap, a pellet, a bead, or a dragee.
  • the dosage form is an orally disintegrating tablet.
  • the dosage form can be a lozenge.
  • the dosage form can be a film.
  • the dosage form can be a chewing gum.
  • the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 40 minutes. In yet another embodiment, the time frame to provide a therapeutically effective plasma concentration of doxepin can be less than about 20 minutes.
  • Some embodiments encompass, the use of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof in the preparation of an orally disintegrable medicament for lessening time to sleep onset in a patient who has insomnia.
  • the orally disintegrable medicament can be formulated to disintegrate in the mouth of a patient in less than 60 seconds without the addition of water.
  • the orally disintegrable medicament can be formulated to disintegrate in the mouth of a patient in less than 30 seconds without the addition of water.
  • the oral disintegrable medicament can have a friability of less than about 2% when tested per the U.S.P.
  • oral disintegrable medicament can have a friability of about 0.8% when tested per the U.S.P. Further, in some embodiments, the oral disintegrable medicament can have a hardness of about 15 Newtons or greater. In a preferred embodiment, the oral disintegrable medicament can have a hardness value in the range of about 20 Newtons to about 60 Newtons. In a further preferred embodiment, the oral disintegrable medicament can have a hardness of about 30 Newtons.
  • Some embodiments encompass, the use of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof, wherein the doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof can comprise a plurality of microparticles of the doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof and a protective material substantially surrounding the doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof.
  • the microparticles can consist essentially of particles from about 75 microns to about 600 microns. Further, in some aspects, the microparticles can comprise about 0.01 to about 75% by weight of the orally disintegrable medicament.
  • the oral disintegrable medicament can further comprise a matrix with a non-direct compression filler and a lubricant.
  • the non-direct compression filler can be a non-direct compression sugar or non-direct compression sugar alcohol.
  • the non-direct compression filler can have an average particle size of about 90 microns or less.
  • the oral disintegrable medicament can further comprise an effervescent agent.
  • the orally disintegrating form of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof can be for use in lessening sleep onset in a patient being treated for insomnia, wherein the orally disintegrating form can be formulated to disintegrate in the mouth of a patient in less than about 60 seconds without water intake; and wherein the orally disintegrating form can be associated with achieving a plasma concentration of doxepin faster than an oral dosage that is not oral disintegrating.
  • a therapeutically effective plasma concentration of doxepin can be achieved in less than 60 minutes.
  • a therapeutically effective plasma concentration of doxepin can be achieved in less than 40 minutes.
  • a therapeutically effective plasma concentration of doxepin can be achieved in less than 20 minutes.
  • the orally disintegrating form can be formulated to disintegrate in the mouth of the patient in a range of about 5 seconds to about 30 seconds.
  • the orally disintegrating form can have a friability of less than about 2% when U.S.P. tested.
  • the orally disintegrating form has a friability of about 0.8% when U.S.P. tested.
  • the orally disintegrating form can have a hardness of about 20 Newtons or greater.
  • the orally disintegrating form can have a hardness in the range of about 20 Newtons to about 60 Newtons.
  • orally disintegrating form can have a hardness of about 30 Newtons.
  • the orally disintegrating form further can include an effervescent agent.
  • the effervescent agent generates evolved gas that can have a volume of about 5 cm 3 to about 30 cm 3 .
  • the effervescent agent can include, but is not limited to, an acid source and a carbonate source, thereby generating a gas.
  • the gas can be carbon dioxide or oxygen.
  • Another embodiment provides a method of treating insomnia, comprising identifying an individual in need of such treatment, and administering any of the compositions disclosed herein to the individual.
  • Yet another embodiment provides a method of enhancing sleep maintenance, comprising identifying an individual in need of such enhancement, and administering any of the compositions disclosed herein to the individual.
  • Some embodiments relate to methods of treating insomnia, which methods can include providing a patient treated with a conventional formulation of a sleep aid and treating said patient with a fast disintegrating form of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof such that time to sleep onset can be reduced.
  • Some embodiments relate to methods of treating insomnia, which methods can include providing a patient treated with a conventional formulation of a sleep aid treating said patient with a fast disintegrating formulation form of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof under conditions such that sleep duration can be maintained into the 8 th hour.
  • Some embodiments relate to methods of treating insomnia, which methods can include providing a patient treated with a conventional formulation of a sleep aid treating said patient with a fast disintegrating formulation form of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof under conditions awakenings after sleep onset are decreased.
  • Some embodiments relate to methods of treating insomnia that can be comprised of treating a patient with a fast disintegrating formulation form of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof under conditions such that sleep duration can be maintained into the 8 th hour.
  • Some embodiments relate to methods of treating insomnia that can be comprised of treating a patient with a fast disintegrating formulation form of doxepin, or a pharmaceutically acceptable salt, prodrug, or metabolite thereof under conditions such that awakenings after sleep onset can be decreased.
  • FIG. 1 is graph simulating absorption of doxepin in the blood plasma over two hours.
  • Embodiments of the invention generally relate to new and surprisingly effective doxepin formulations and methods of using low-dose forms of doxepin, including, for example, use in the treatment of insomnia.
  • some preferred embodiments relate to buccal, sublingual and fastmelt doxepin formulations, as well as methods of using the same.
  • some embodiments of this invention relate to novel and economic methods of manufacturing low-dose dosage forms of doxepin, pharmaceutically acceptable salts thereof, or other doxepin-related compounds.
  • doxepin to treat sleep disorders, in particular low dose doxepin
  • doxepin is taken orally (e.g., tablets and capsules) and swallowed much of the drug is transported directly to the liver before it can enter the bloodstream.
  • some of the drug is metabolized in the liver before reaching the bloodstream or the intended site in the body.
  • swallowed doxepin also may be degraded in the gastrointestinal tract.
  • some embodiments relate to doxepin formulations that can be administered orally, sublingually, buccally so that more of the drug can be taken into the bloodstream before it is metabolized by the liver or degraded in the stomach.
  • Doxepin is a tricyclic compound currently approved for treatment of depression or anxiety at a daily dose of 75 mg to 300 mg.
  • Doxepin is marketed under the commercial name SINEQUAN® and in generic form, and can be obtained in the United States generally from pharmacies in capsule form in amounts of 10, 25, 50, 75, 100 and 150 mg dosage, and in liquid concentrate form at 10 mg/mL.
  • the capsule formulations contain Doxepin HCl with cornstarch and magnesium stearate/sodium lauryl sulfate.
  • Capsule shells can also contain gelatin, sodium lauryl sulfate, sodium metabisulfate and colorants.
  • Doxepin HCl is a tricyclic compound currently approved and available for treatment of depression and anxiety. Doxepin has the following structure:
  • Doxepin can be depicted as follows:
  • Doxepin belongs to a class of psychotherapeutic agents known as dibenzoxepin tricyclic compounds, and is currently approved and prescribed for use as an antidepressant to treat depression and anxiety. Doxepin has a well-established safety profile, having been prescribed for over 35 years.
  • doxepin for use in the compositions and methods described herein can be obtained from any suitable source or made by any suitable method.
  • doxepin HCl can be obtained from Plantex Ltd. (DMF No. 3230).
  • doxepin HCl, USP is designated as a Class One compound, with high solubility and high permeability (Wu-Benet, 2005).
  • the Plantex-supplied doxepin HCl, USP has a particle size specification of not less than 80% smaller than 38 microns and not less than 90% smaller than 125 microns as measured by an Air Jet Sieve method.
  • doxepin can be prepared according to the method described in U.S. Pat. No.
  • doxepin metabolites can be prepared and used.
  • some examples of metabolites of doxepin can include, but are not limited to, doxepin, hydroxydoxepin, hydroxyl-N-doxepin, doxepin N-oxide, N-acetyl-N-doxepin, N-desmethyl-N-formyldoxepin, quaternary ammonium-linked glucuronide, 2-O-glucuronyldoxepin, didoxepin, 3-O-glucuronyldoxepin, or N-acetyldidoxepin.
  • the metabolites of doxepin can be obtained or made by any suitable method, including the methods described above for doxepin.
  • Doxepin has the following structure:
  • Doxepin is commercially available as a forensic standard. For example, it can be obtained from Cambridge Isotope Laboratories, Inc. (50 Frontage Road, Andover, Mass.). Doxepin for use in the methods discussed herein can be prepared by any suitable procedure.
  • doxepin can be prepared from 3-methylaminopropyl triphenylphosphonium bromide hydrobromide and 6,11-dihydrodibenz(b,e)oxepin-11-one according to the method taught in U.S. Pat. No. 3,509,175, which is incorporated herein by reference in its entirety.
  • doxepin can be from doxepin hydrochloride as taught in U.S. Pat. No. 5,332,661, which is incorporated herein by reference in its entirety.
  • Hydroxydoxepin has the following structure:
  • 2-Hydroxydoxepin can be prepared by any suitable method, including as taught by Shu et al. (Drug Metabolism and Disposition (1990) 18:735-741), which is incorporated herein by reference in its entirety.
  • Hydroxyl-N-doxepin has the following structure:
  • 2-Hydroxy-N-doxepin can be prepared any suitable method.
  • Doxepin N-oxide has the following structure:
  • Doxepin-N-oxide can be prepared by any suitable method.
  • doxepin-N-oxide can be prepared as taught by Hobbs ( Biochem Pharmacol (1969) 18:1941-1954), which is hereby incorporated by reference in its entirety.
  • N-acetyl-N-doxepin has the following structure:
  • N-acetyl-N-doxepin can be prepared by any suitable means.
  • N-acetyl-N-doxepin has been produced in filamentous fungus incubated with doxepin as taught by Moody et al. (Drug Metabolism and Disposition (1999) 27:1157-1164), hereby incorporated by reference in its entirety.
  • N-desmethyl-N-formyldoxepin has the following structure:
  • N-desmethyl-N-formyldoxepin can be prepared by any suitable means.
  • N-desmethyl-N-formyldoxepin has been produced in filamentous fungus incubated with doxepin as taught by Moody et al. (Drug Metabolism and Disposition (1999) 27:1157-1164), hereby incorporated by reference in its entirety.
  • N-acetyldidoxepin has the following structure:
  • N-acetyldidoxepin can be prepared by any suitable means.
  • N-acetyldidoxepin has been produced in filamentous fungus incubated with doxepin as taught by Moody et al. (Drug Metabolism and Disposition (1999) 27:1157-1164), hereby incorporated by reference in its entirety.
  • Didoxepin has the following structure:
  • Didoxepin can be prepared by any suitable means.
  • didoxepin has been isolated from plasma and cerebrospinal fluid of depressed patients taking doxepin, as taught by Deuschle et al. (Psychopharmacology (1997) 131:19-22), hereby incorporated by reference in its entirety.
  • 3-O-glucuronyldoxepin has the following structure:
  • 3-O-glucuronyldoxepin can be prepared by any suitable means.
  • 3-O-glucuronyldoxepin has been isolated from the bile of rats given doxepin, as described by Shu et al. (Drug Metabolism and Disposition (1990)18:1096-1099), hereby incorporated by reference in its entirety.
  • 2-O-glucuronyldoxepin has the following structure:
  • 2-O-glucuronyldoxepin can be prepared by any suitable means.
  • 2-O-glucuronyldoxepin has been isolated from the bile of rats given doxepin, and also in the urine of humans given doxepin, as described by Shu et al. (Drug Metabolism and Disposition (1990) 18:1096-1099), hereby incorporated by reference in its entirety.
  • Quaternary ammonium-linked glucuronide of doxepin (doxepin N + -glucuronide) has the following structure:
  • N + -glucuronide can be obtained by any suitable means.
  • doxepin N + -glucuronide can be prepared, and can be isolated as taught by Luo et al. (Drug Metabolism and Disposition, (1991) 19:722-724), hereby incorporated by reference in its entirety.
  • the methods and other embodiments described herein can utilize any suitable pharmaceutically acceptable salt or prodrug of doxepin or salts or prodrugs of doxepin metabolites. Therefore, the substitution or use in combination of salts and prodrugs is specifically contemplated in the embodiments described herein.
  • the pharmaceutically acceptable salts and prodrugs can be made by any suitable method.
  • pharmaceutically acceptable salt refers to an ionic form of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glutamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
  • a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glutamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
  • the acids that can be used to prepare pharmaceutically acceptable acid addition salts include, for example, those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, dislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate,
  • the bases that can be used to prepare pharmaceutically acceptable base addition salts include, for example, those that form non-toxic base addition salts, i.e., base salts formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
  • metals used as cations include sodium, potassium, magnesium, calcium, and the like.
  • heavy metal salts such as for example silver, zinc, cobalt, and cerium.
  • suitable amines include N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamene, N-methylglucamine, and procaine.
  • prodrug refers to an agent that is converted into the active drug in vivo. Prodrugs are often useful because, in some situations, they can be easier to administer than the active drug. They can, for instance, be bioavailable by oral administration whereas the active drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the active drug.
  • An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • prodrug groups can be found in, for example, T. Higuchi and V. Stella, in “Pro-drugs as Novel Delivery Systems,” Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975); H. Bundgaard, “Design of Prodrugs,” Elsevier Science, 1985; and “Bioreversible Carriers in Drug Design: Theory and Application,” edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987), each of which is hereby incorporated by reference in its entirety.
  • Dosage form development can require the selection of excipients based on the properties of the drug substance being formulated. Several preferred embodiments of this invention are provided. These should not be construed as limiting the scope of this invention.
  • Some embodiments of the invention are based upon the new discovery of physical characteristics and challenges associated with low-dose doxepin compositions, such as, uniformity and/or potency, and also upon a new understanding of pharmacokinetics of doxepin when it is used to treat sleep disorders.
  • the target pharmacokinetic profile for the orally disintegrating formulation is designed to preserve the pharmacokinetic profile of a standard oral dosage form (i.e., maintenance and duration) but with a more rapid onset.
  • compositions at the lower dose range can present a considerable challenge in maintaining consistent potency and uniformity in the drug product manufacturing process, while also maintaining a high yield.
  • assuring the homogeneity of the powder blend for production of low-dose dosage forms can represent a major quality assurance consideration.
  • the selection of the particular excipient or excipients used, and how to properly blend and prevent non-uniformity and segregation were based upon previously unrecognized characteristics and needs for doxepin formulation, particularly low-dose formulations.
  • the compositions are based upon previously unknown pharmacokinetics of low-dose doxepin for sleep.
  • doxepin dissolves quickly in the stomach, it undergoes a significant first pass extraction or metabolism in the liver. Thus, it can take some time for the sleep promoting action of the drug to take place.
  • No one previously recognized the sleep pharmacokinetics of doxepin, such as, sleep onset characteristics of doxepin; and for sleep, even decreasing induction time by a few minutes can provide an enormous benefit.
  • early onset of drug action can be important due to the discreet window of time (e.g., 8 hours) in which a patient needs to sleep.
  • compositions that can contribute to accelerated action of the drug. That need was not recognized previously, in particular for depression and anxiety where there was no need for fast onset due to the ongoing and chronic nature of those conditions. The unique needs of doxepin for treating sleep were not appreciated in the prior art.
  • compositions for the treatment of such disorders where careful selection of excipients was used to address the previously unrecognized characteristics of low-dose doxepin and doxepin for use in treating sleep disorders. Described below and elsewhere herein are new and unexpectedly effective doxepin formulations.
  • Doxepin HCl, USP is a white crystalline powder with a slight amine-like odor supplied by Plantex Ltd.
  • doxepin HCl, USP is designated as a Class One compound, with high solubility and high permeability (Wu-Benet, 2005).
  • the Plantex-supplied doxepin HCl, USP has a particle size specification of not less than 80% smaller than 38 microns and not less than 90% smaller than 125 microns as measured by an Air Jet Sieve method.
  • the compositions disclosed herein can include from about 0.01 mg to about 9 mg of doxepin, or from about 0.5 mg to about 7 mg doxepin, or from about 1 mg to about 6 mg doxepin. In some embodiments, the compositions include from about 0.5 mg to about 2 mg doxepin, or from about 2.5 mg to about 4 mg, or from about 5.9 mg to about 7 mg doxepin.
  • low-dose metabolites of doxepin, doxepin prodrugs or pharmaceutically acceptable salts of doxepin, or other doxepin-related compounds can be used in place of, or in addition to, low-dose doxepin in the formulations described herein.
  • Some embodiments provide low-dose doxepin tablets, lozenges, chewing gum, capsules, caplets, pills, gel caps, pellets, beads, or dragee dosage forms that can be absorbed across the oral mucosa. Some embodiments specifically exclude one or more such dosage forms.
  • the formulations disclosed herein can provide favorable drug processing qualities, including, for example, but not limited to, rapid tablet press speeds, reduced compression force, reduced ejection forces, blend uniformity, content uniformity, uniform dispersal of color, accelerated disintegration time, rapid dissolution, low friability (preferable for downstream processing such as packaging, shipping, pick-and-pack, etc.) and dosage form physical characteristics (e.g., weight, hardness, thickness, friability) with little variation.
  • favorable drug processing qualities including, for example, but not limited to, rapid tablet press speeds, reduced compression force, reduced ejection forces, blend uniformity, content uniformity, uniform dispersal of color, accelerated disintegration time, rapid dissolution, low friability (preferable for downstream processing such as packaging, shipping, pick-and-pack, etc.) and dosage form physical characteristics (e.g., weight, hardness, thickness, friability) with little variation.
  • Many of these qualities notably, content uniformity and blend uniformity, are difficult to obtain in low dose formulations.
  • the invention described herein provides a hard, compressed, fast disintegrating tablet adapted for oral administration, preferably for oral transmucosal administration.
  • the tablet can include particles made of an active ingredient and a protective material. These particles can be provided in an amount of between about 0.01 and about 75% by weight based on the weight of the tablet, for example.
  • the tablet can also include a matrix made from a nondirect compression filler, a wicking agent, and a hydrophobic lubricant.
  • the preferred tablet matrix can comprise, for example, at least about 60% rapidly water-soluble ingredients based on the total weight of the matrix material.
  • the preferred tablet can have, for example, a hardness of between about 2 Kp to about 6 Kp, a friability of less than 0.8% when measured by U.S.P. and is adapted to disintegrate spontaneously in the mouth of a patient in less than about 60 seconds (and, more preferably, less than about 30 seconds) thereby liberating said particles.
  • the tablets are capable of being stored in bulk.
  • the invention described herein provides a compressed fast disintegrating tablet comprising effervescent agents.
  • effervescent pharmaceutical compositions suitable for use and adaptation in conjunction with some of the present embodiments include the compositions described in Pather, U.S. Pat. No. 6,200,604, which is incorporated herein by reference in its entirety.
  • compositions suitable for use and adaptation in conjunction with the compositions disclosed herein are described in U.S. Pat. No. 5,178,878 to Wehling, et al., U.S. Pat. No. 5,223,264 to Wehling, et al. and U.S. Pat. No. 6,024,981 to Khankari et al., each of which is hereby incorporated by reference in its entirety.
  • the invention described herein provides a dosage form as a fast disintegrating ordered-mixture composition as disclosed in European patent EP 0 324 725 (herein incorporated by reference).
  • doxepin covers (in a finely dispersed state) the surface of substantially larger carrier particles.
  • Such compositions disintegrate rapidly in water, thereby dispersing their contents of microscopic drug particles.
  • the present invention describes a hard, compressed, fast disintegrating tablet, formulated with an antidepressant, adapted for oral administration.
  • the tablet can include particles made of an active ingredient and a protective material. These particles can be provided in an amount of between about 0.01 and about 75% by weight based on the weight of the tablet.
  • the tablet can also include a matrix made from a nondirect compression filler, a wicking agent, and a lubricant.
  • the preferred tablet matrix comprises at least about 60% rapidly water-soluble ingredients based on the total weight of the matrix material.
  • the preferred tablet has a hardness of between about 20 and about 60 Newtons, a friability of less than 1% when measured by U.S.P. and is adapted to disintegrating spontaneously in the mouth of a patient in less than about 60 seconds (and, more preferably, less than about 30 seconds) and thereby liberate said particles and be capable of being stored in bulk.
  • the invention described herein provides a method for reducing time to sleep onset comprising providing a patient treated with a fast disintegrating formulation of doxepin under conditions such that time to sleep onset is reduced.
  • said fast disintegrating doxepin formulation is an ODT.
  • the invention provides a method for maintaining sleep for 8 hours comprising providing a patient treated with a fast disintegrating formulation of doxepin under conditions such that sleep time duration is maintained for 7 to 8 hours.
  • said fast disintegrating doxepin formulation is an orally disintegrating tablet (ODT).
  • the invention described herein provides a method for reducing awakening after sleep onset comprising providing a patient treated with a fast disintegrating formulation of doxepin under conditions such that awakenings are reduced after sleep onset.
  • said fast disintegrating doxepin formulation is an ODT.
  • a quick dissolve delivery system is used in the orally disintegrating formulations described herein.
  • the quick dissolve delivery system is a directly compressible excipient for orally disintegrating tablet formulations.
  • the quick dissolve excipient can be, but is not limited to, RxCIPIENTSTTM FM1000, Pharmaburst, or F-MeltTM.
  • the orally disintegrating tablet can dissolve within 5 minute.
  • the orally disintegrating tablet can dissolve within 1 minute.
  • the amount of doxepin in the formulation can be from about 0.1 to about 9 mg.
  • the compositions disclosed herein can include doxepin in the amount of about 0.1 to 20% of the total formulation amount and Pharmaburst in the amount of about 50% to about 90%, or from about 60% to about 85%, or from about 70% to about 80% of the total formulation amount.
  • the amount of doxepin in the formulation can be from about 0.1 to about 9 mg.
  • the amount of doxepin can be 3 mg (3%) and the amount of Pharmaburst can be 85 mg (85%) in a 100 mg tablet.
  • the amount of doxepin can be 3 mg (4%) and the amount of Pharmaburst can be 61.8 mg (82.4%) in a 75 mg tablet.
  • the amount of doxepin can be 1 mg (1%) and the amount of Pharmaburst can be 87 mg (87%) in a 100 mg tablet. In a further preferred embodiment, the amount of doxepin can be 1 mg (1.3%) and the amount of Pharmaburst can be 61.8 mg (82.4%) in a 75 mg tablet.
  • the compositions disclosed herein can include RxCIPIENTSTM FM1000 in the amount of about 15 to about 35%, or from about 20% to about 30% of the total formulation amount and doxepin in the amount of about 0.1 to 20% of the total formulation.
  • the amount of doxepin in the formulation can be from about 0.1 to about 9 mg.
  • the amount of doxepin in the can be 3 mg (3%) and the amount of RxCIPIENTSTM FM1000 can be 29.4 mg (29.4%) in a 100 mg tablet.
  • the amount of doxepin can be 3 mg (4%) and the amount of RxCIPIENTSTM FM1000 can be 22.05 mg (29.4%) in a 75 mg tablet.
  • the amount of doxepin can be 1 mg (1%) and the amount of RxCIPIENTSTM FM1000 can be 32.4 mg (32.4%) in a 100 mg tablet. In some embodiments, the amount of doxepin can be 1 mg (1.3%) and the amount of RxCIPIENTSTM FM1000 can be 22.05 mg (29.4%) in a 75 mg tablet.
  • the compositions disclosed herein can comprise F-MeltTM as the excipient in the amount of about 25 to 65%, or from about 30% to about 62%, or from about 40% to about 60% of the total formulation amount and doxepin in the amount of about 0.1 to 20% of the total formulation amount.
  • the amount of doxepin in the formulation can be from about 0.1 to about 9 mg.
  • the amount of doxepin in the can be 3 mg (3%) and the amount of F-MeltTM can be 58 mg (58%) in a 100 mg tablet.
  • the amount of doxepin can be 3 mg (4%) and the amount of F-MeltTM can be 43.4 mg (58%) in a 75 mg tablet.
  • the amount of doxepin can be 1 mg (1%) and the amount of F-MeltTM can be 60 mg (60%) in a 100 mg tablet. In some embodiments, the amount of doxepin can be 1 mg (1.3%) and the amount of F-MeltTM can be 43.5 mg (58%) in a 75 mg tablet.
  • the doxepin compositions disclosed herein can be formulated as disclosed in Drug Delivery to the Oral Cavity: Molecules to Market, Ghosh and Pfister, eds., 2005, Taylor & Francis, which is hereby incorporated by reference in its entirety.
  • doxepin can be formulated using any commercially available orally disintegrating technologies such as, for example, but not limited to, FlashDose®, Zydis, OraSolv, DuraSolv, FlastTab, AdvaTabTM, OraQuick®, Lyoc®, SATAB, WOWTAB, and the like.
  • the formulations can yield extremely rapid disintegration times of 1 minute or less as per USP protocols.
  • the formulation yields disintegration times of 60, 50, 40, 30, 25 seconds or less.
  • the formulation yields a rapidly orally disintegrating dosage form, for which greater than 85% of the doxepin containing dosage form dissolves within 5 minutes. In some embodiments the formulation yields a rapidly orally dissolving dosage form, for which 65% to 85% of the doxepin containing dosage form dissolves within 5 minutes. In some embodiments, the formulation yields a rapidly orally dissolving dosage form, for which 45% to 65% of the doxepin containing dosage form dissolves within 5 minutes. In some embodiments, the formulation yields a rapidly orally dissolving dosage form, for which 25% to 45% of the doxepin containing dosage form dissolves within 5 minutes. In some embodiments, the formulation yields a rapidly orally disintegrating dosage form, for which 5% to 25% of the doxepin containing dosage form dissolves within 5 minutes.
  • the formulation yields a rapidly orally disintegrating dosage form, for which 5% to 25% of the doxepin containing dosage form dissolves within 1 minute. In a preferred embodiment, the formulation yields a rapidly orally dissolving dosage form, for which 25% to 45% of the doxepin containing dosage form dissolves within 1 minute. In another preferred embodiment, the formulation yields a rapidly orally dissolving dosage form, for which 45% to 85% of the doxepin containing dosage form dissolves within 1 minute. In further preferred embodiments, the formulation yields a rapidly orally dissolving dosage form, for which 85% to 99% of the doxepin containing dosage form dissolves within 1 minute. In some aspects nearly 100% of the rapidly orally disintegrating dosage form containing doxepin dissolves within 1 minute.
  • the formulation yields a rapidly orally disintegrating dosage form, for which greater than 85% of the doxepin is absorbed across the oral mucosa within 5 minutes. In some embodiments the formulation yields a rapidly orally disintegrating dosage form, for which 65% to 85% of the doxepin is absorbed across the oral mucosa within 5 minutes. In some embodiments, the formulation yields a rapidly orally disintegrating dosage form, for which 45% to 65% of the doxepin is absorbed across the oral mucosa within 5 minutes. In some embodiments, the formulation yields a rapidly orally disintegrating dosage form, for which 25% to 45% of the doxepin is absorbed across the oral mucosa within 5 minutes. In some embodiments, the formulation yields a rapidly orally disintegrating dosage form, for which 5% to 25% of the doxepin is absorbed across the oral mucosa within 5 minutes.
  • the formulation yields a rapidly orally disintegrating dosage form, for which 5% to 25% of the doxepin is absorbed across the oral mucosa within 1 minute. In a preferred embodiment, the formulation yields a rapidly orally disintegrating dosage form, for which 25% to 45% of the doxepin is absorbed across the oral mucosa within 1 minute. In another preferred embodiment, the formulation yields a rapidly orally disintegrating dosage form, for which 45% to 85% of the doxepin is absorbed across the oral mucosa within 1 minute. In further preferred embodiments, the formulation yields a rapidly orally disintegrating dosage form, for which 85% to 99% of the doxepin is absorbed across the oral mucosa within 1 minute. In some aspects nearly 100% of the doxepin is absorbed across the oral mucosa within 1 minute.
  • a therapeutic blood plasma level of doxepin is achieved within 40 minutes of administering a rapidly orally disintegrating dosage containing 9 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 20 minutes of administering a rapidly orally disintegrating dosage containing 9 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 40 minutes of administering a rapidly orally disintegrating dosage containing 6 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 20 minutes of administering a rapidly orally disintegrating dosage containing 6 mg of doxepin.
  • a therapeutic blood plasma level of doxepin is achieved within 40 minutes of administering a rapidly orally disintegrating dosage containing 3 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 20 minutes of administering a rapidly orally disintegrating dosage containing 3 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 40 minutes of administering a rapidly orally disintegrating dosage containing 1 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 20 minutes of administering a rapidly orally disintegrating dosage containing 1 mg of doxepin.
  • a therapeutic blood plasma level of doxepin is achieved within 40 minutes of administering a rapidly orally disintegrating dosage containing 0.5 mg of doxepin. In other embodiments, a therapeutic blood plasma level of doxepin is achieved within 20 minutes of administering a rapidly orally disintegrating dosage containing 0.5 mg of doxepin.
  • the low-dose dosage forms described herein are formulated to yield two or more favorable drug characteristics.
  • the compounds can be formulated readily, for example, by combining the drug substance with any suitable pharmaceutically acceptable excipient for example, but not limited to, binders, diluents, disintegrants, lubricants, fillers, carriers, and the like, as set forth below.
  • suitable pharmaceutically acceptable excipient for example, but not limited to, binders, diluents, disintegrants, lubricants, fillers, carriers, and the like, as set forth below.
  • Such compositions can be prepared for storage and for subsequent processing.
  • carrier material or “excipient” herein can mean any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a tablet, lozenge, chewing gum, capsule, caplet, gel cap, pill, pellet, bead, and the like suitable for oral administration.
  • Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, colorants, fragrances, and substances added to improve appearance of the composition.
  • Acceptable excipients include, for example, but are not limited to, RxCIPIENTSTM FM1000, Pharmaburst, F-MeltTM, Starch 1500®, microcrystalline cellulose, lactose, sucrose, starch powder, maize starch or derivatives thereof, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinyl-pyrrolidone, and/or polyvinyl alcohol, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like.
  • suitable excipients for soft gelatin capsules include vegetable oils, waxes, fats, semisolid and liquid polyols.
  • suitable excipients for the preparation of solutions and syrups include, without limitation, water, polyols, sucrose, invert sugar and glucose.
  • the compound can also be made in microencapsulated form. If desired, absorption enhancing preparations (for example, liposomes), can be utilized.
  • compositions and formulations can include any other agents that provide improved transfer, delivery, tolerance, and the like.
  • These compositions and formulations can include, for example, powders, pastes, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax.
  • any of the foregoing mixtures can be appropriate in treatments and therapies in accordance with the invention disclosed herein, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See also Baldrick P. “Pharmaceutical excipient development: the need for preclinical guidance.” Regul. Toxicol. Pharmacol. 32(2):210-8 (2000), Charman WN “Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.” J Pharm Sci 89(8):967-78 (2000), and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.
  • one or more, or any combination of the listed excipients can be specifically included or excluded from the formulations and/or methods disclosed herein.
  • microcrystalline cellulose can be specifically excluded.
  • Oral administration can be accomplished using orally administered formulations, for example, tablets, chewing gums, lozenges, films, capsules, gel caps, caplets, pellets, beads, pills, and the like.
  • stabilizers can be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the amounts of excipients will be determined by drug dosage and dosage form size.
  • the dosage form size is 100 mg.
  • This dosage form weight is arbitrary and one skilled in the art will realize that a range of weights can be made and are encompassed by this invention.
  • the preferred dosage form range is 50 mg to 200 mg, more preferably 50 mg to 150 mg, more preferably 75 to 100 mg, with the preferred dosage form weight being 100 mg.
  • low doses of doxepin are combined with any commercially available quick dissolve delivery system, such as, for example, but not limited to, RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, and the like.
  • RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM a commercially available quick dissolve delivery system
  • the range of drug substance is from about 0.75% to about 4.5% w/w and the range of RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, is from about 15 to 35% w/w, or from about 50% to about 90% w/w, or from about 25% to about 65% w/w, respectively.
  • a dry pharmaceutical blend of a preferred orally disintegrating excipient such as, for example, but not limited to, RxCIPIENTSTM FM1000, Pharmaburst, F-MeltTM, and the like and low-dose doxepin, or a low-dose doxepin-related compound, can be used to produce the final dosage form by direct compression.
  • the dry blend can contain from about 0.1% to about 10% w/w, or from about 0.5% to about 5% w/w, or from about 0.7% to about 4.5% w/w of low-dose doxepin or a low-dose doxepin-related compound.
  • the doxepin or doxepin-related compound, in the dry blend can be non-granulated.
  • the blend can contain from about 15% to about 30% w/w RxCIPIENTSTM, or from about 25% to about 65% w/w F-MeltTM, or from about 50% to about 90% w/w Pharmaburst, or the like.
  • an orally disintegrating excipient such as RxCIPIENTSTM FM1000, Pharmaburst, F-MeltTM, and the like can be combined or replaced with one or more of the following excipients: microcrystalline cellulose, lactose monohydrate (spray dried), a compressible sugar, xylitol (Xylitab), sorbitol, mannitol, pregelatinized starch, maltodextrin, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate DC, and the like.
  • excipients microcrystalline cellulose, lactose monohydrate (spray dried), a compressible sugar, xylitol (Xylitab), sorbitol, mannitol, pregelatinized starch, maltodextrin, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate DC, and the like.
  • one or more of the above excipients can be combined with a preferred excipient, such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, and the like, in various ratios.
  • a preferred excipient such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, and the like, in various ratios.
  • a preferred excipient such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, can be combined with about 20% of one or more alternate filler(s).
  • about 70% of a preferred excipient such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM
  • about 30% of one or more alternate filler(s) or about 60% of a preferred excipient, such as RxCIPIENTSTM FM1000, or Pharmaburst, F-MeltTM
  • about 40% of one or more alternate filler(s) or about 50% of a preferred excipient, such as RxCIPIENTSTM FM1000, or Pharmaburst, F-MeltTM, can be combined with about 50% of one or more alternate filler(s), or about 40% of a preferred excipient, such as RxCIPIENTSTM FM1000, or Pharmaburst, F-MeltTM, can be combined with about 60% of one or more alternate filler(s), or about 30% of a preferred excipient, such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, can be combined with
  • a preferred excipient such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM
  • alternate excipients are selected to provide favorable drug processing qualities. Other favorable quick dissolve delivery systems will be apparent to one of skill in the art.
  • the dry blend can also include at least one additional pharmaceutically acceptable suitable excipient.
  • Additional excipients can include processing aids that improve the direct compression tablet-forming properties of the dry blend, and/or powder flowability.
  • excipients suitable for use in direct compression include, but are not limited to, binders, diluents, disintegrants, lubricants, fillers, carriers, and the like as set forth above.
  • the formulation comprises a mixture of the drug substance with a preferred excipient, such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, and the like, along with additional processing aides, such as, for example, magnesium stearate and colloidal silicon dioxide, and optionally, colorant(s).
  • a preferred excipient such as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM, and the like
  • additional processing aides such as, for example, magnesium stearate and colloidal silicon dioxide, and optionally, colorant(s).
  • magnesium stearate can be added as a lubricant, for example, to improve powder flow, prevent the blend from adhering to tableting equipment and punch surfaces and provide lubrication to allow tablets to be cleanly ejected from tablet dies.
  • Magnesium stearate can typically be added to pharmaceutical formulations at concentrations ranging from about 0.1% to about 5.0% w/w, or from about 0.25% to about 2% w/w, or from about 0.5% to about 1% w/w.
  • color additives also can be included.
  • the colorants can be used in amounts sufficient to distinguish dosage form strengths.
  • color additives approved for use in drugs (21 CFR 74) are added to the commercial formulations to differentiate tablet strengths.
  • the use of other pharmaceutically acceptable colorants and combinations thereof are encompassed by the current invention.
  • Binders can be used, for example, to impart cohesive qualities to a formulation, and thus ensure that the resulting dosage form remains intact after compaction.
  • Suitable binder materials include, but are not limited to, microcrystalline cellulose, gelatin, sugars (including, for example, sucrose, glucose, dextrose and maltodextrin), polyethylene glycol, waxes, natural and synthetic gums, polyvinylpyrrolidone, cellulosic polymers (including, for example, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, hydroxyethyl cellulose, and the like).
  • the formulations disclosed herein can include at least one binder to enhance the compressibility of the major excipient(s).
  • the formulation can include at least one of the following binders in the following preferred ranges: from about 2 to about 6% w/w hydroxypropyl cellulose (Klucel), from about 2 to about 5% w/w polyvinylpyrrolidone (PVP), from about 1 to about 5% w/w methycellulose, from about 2 to about 5% hydroxypropyl methycellulose, from about 1 to about 5% w/w ethylcellulose, from about 1 to about 5% w/w sodium carboxy methylcellulose, and the like.
  • the above ranges are exemplary preferred ranges.
  • binders and/or amounts that can be used in the formulations described herein.
  • the amounts of the major filler(s) and/or other excipients can be reduced accordingly to accommodate the amount of binder added in order to keep the overall unit weight of the tablet unchanged.
  • the binder(s) is sprayed on from solution, e.g. wet granulation, to increase binding activity.
  • Lubricants can be employed herein-in the manufacture of certain dosage forms. For example, a lubricant will often be employed when producing tablets. In an embodiment of the invention disclosed, a lubricant can be added just before the tableting step, and can be mixed with the formulation for a minimum period of time to obtain good dispersal. In some embodiments, one or more lubricants can be used.
  • Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, glyceryl behenate, polyethylene glycol, polyethylene oxide polymers (for example, available under the registered trademarks of Carbowax® for polyethylene glycol and Polyox® for polyethylene oxide from Dow Chemical Company, Midland, Mich.), sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, DL-leucine, colloidal silica, and others as known in the art.
  • Lubricants are sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate and mixtures of magnesium stearate with sodium lauryl sulfate.
  • Lubricants can comprise from about 0.25% to about 10% of the tablet weight, more preferably from about 0.5% to about 3%.
  • the formulations disclosed herein can include at least one lubricant in the following preferred ranges: from about 0.25 to about 2% w/w magnesium stearate, from about 0.25 to about 2% w/w calcium stearate, from about 0.25 to about 2% w/w sodium stearyl fumarate, from about 0.25 to about 2% w/w stearic acid, from about 0.25 to about 2% w/w hydrogenated vegetable oil, from about 0.25 to about 2% w/w glyceryl behenate, from about 0.25 to about 2% w/w polyethylene glycol 4000-6000, and the like.
  • the above ranges are examples of preferred ranges.
  • Disintegrants can be used, for example, to facilitate tablet disintegration after administration, and are generally starches, clays, celluloses, algins, gums or crosslinked polymers. Suitable disintegrants include, but are not limited to, crosslinked polyvinylpyrrolidone (PVP-XL), sodium starch glycolate, and croscarmellose sodium.
  • PVP-XL crosslinked polyvinylpyrrolidone
  • sodium starch glycolate sodium starch glycolate
  • croscarmellose sodium croscarmellose sodium
  • the pharmaceutical formulation can also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, polyoxyethylene sorbitan fatty acid esters, etc.
  • nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, polyoxyethylene sorbitan fatty acid esters, etc.
  • At least one additional disintegrant can be included in the following preferred ranges: from about 1 to about 3% w/w croscarmellose sodium, from about 4 to about 6% w/w sodium starch glycolate, from about 2 to about 4% w/w crospovidone, from about 10 to about 20% w/w microcrystalline cellulose, from about 5 to about 10% w/w pregelatinized starch, from about 5 to about 10% w/w corn starch, from about 5 to about 10% w/w alginic acid, from about 1 to about 5% w/w ion exchange resin (Amberlite 88), and the like.
  • the above ranges are examples of preferred ranges.
  • disintegrants and/or amounts of disintegrants that can be used in the formulations described herein.
  • the amounts of the major filler(s) and/or other excipients can be reduced accordingly to accommodate the amount of disintegrant added in order to keep the overall unit weight of the tablet unchanged.
  • the selected dosage level can depend upon, for example, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved with an acceptable safety profile. It will be understood, however, that the specific dose level for any particular patient can depend upon a variety of factors including, for example, the genetic makeup, body weight, general health, diet, time and route of administration, combination with other drugs and the particular condition being treated, and its severity. For the treatment of insomnia, preferably one dose is administered prior to bedtime.
  • the term “unit dosage form,” refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of doxepin calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable excipient, carrier or vehicle.
  • the unit dosage form is, for example, a tablet, a lozenge, a chewing gum, a film, a capsule, a pill, a caplet, a gel cap, a pellet, a bead, or the like.
  • the unit dosage form is a tablet.
  • the amount of doxepin in a unit dosage form is about 0.5 mg to about 9 mg, or about 1 mg to about 9 mg, or about 1 mg to about 6 mg.
  • daily dosages of low dose doxepin can be about 1, 2, 3, 4, 5, 6, 7, 8, or 9 milligrams. In one embodiment, an initial daily dosage of about 1 milligram can be given. If the desired improvement in sleep is not achieved, then the dosage can be incrementally increased until the desired effect is achieved or until a maximum desired dosage is reached which can be, for example, 2 milligrams, 3 milligrams, 4 milligrams, 5 milligrams or 6 milligrams. It should be noted that other dosages of doxepin can be used in the embodiments described herein. For example, the dosage can be about 0.5 to about 10 milligrams.
  • low dose can refer to a daily dose range of between about 0.01 and 9 milligrams, or to even lower doses.
  • the preferable dosage of doxepin can be between about 0.1 milligram and 9 milligrams.
  • the dosage can be about 0.1 milligrams, about 0.2 milligrams, about 0.3 milligrams, about 0.5 milligrams, about 1 milligram, about 2 milligrams, about 3 milligrams, about 4 milligrams, about 5 milligrams, 6 milligrams, about 7 milligrams, about 8 milligrams, or about 9 milligrams.
  • formulations and methods described herein can be applied to any dosage of doxepin, including higher doses used to treat depression and anxiety.
  • formulations and methods can be applied to dosages between about 10 milligrams and 20 milligrams or higher.
  • compositions for oral use can be obtained by mixing one or more solid excipients with a pharmaceutical composition as described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets.
  • the compositions are prepared using a dry granulation process.
  • a wet granulation process can be used.
  • fluid bed granulation processing techniques are used.
  • One such granulation method is the “wet” granulation process, wherein dry solids (drug substance, filler, binder etc.) are blended and moistened with water or another wetting agent (e.g. an alcohol) and agglomerates or granules are built up of the moistened solids. Wet massing is continued until a desired homogenous particle size has been achieved whereupon the granulated product is dried.
  • dry solids drug substance, filler, binder etc.
  • water or another wetting agent e.g. an alcohol
  • compositions disclosed herein are prepared using direct compression.
  • use of wet granulation techniques is specifically excluded.
  • direct compression means that the solid unit dosage form is prepared by compression of a simple mixture of the active pharmaceutical ingredient and excipients, without the active ingredient having been subjected to an intermediate granulation process in order to embed it in a larger particle and improve its fluidity properties.
  • the formulation ingredients including the active pharmaceutical ingredient and processing aids, are incorporated into a free flowing blend.
  • the active ingredient, excipients, and other substances are blended and then compressed into tablets. Tablets are typically formed by pressure being applied to a material in a tablet press.
  • Advantages of direct compression over wet and dry granulation processes include, for example, shorter processing times and cost advantages.
  • a dry blend is used in forming low-dose doxepin or doxepin-related compound tablets through gravity-fed, direct compression tableting.
  • gravity fed tableting press it is meant that a pharmaceutical formulation is not force fed into a die, and that the flow of the pharmaceutical formulation is induced by gravity.
  • An example of a gravity fed tableting press is the Manesty F-press.
  • the doxepin hydrochloride tablet products disclosed herein are manufactured with common and simple processes including direct blending and compression using commercially available pharmaceutical equipment. These operations utilize readily available equipment, do not expose the API to moisture and heat, and are scalable.
  • the commercial manufacturing process produces and maintains blends and unit dosage forms with uniform potency that meet all quality characteristics.
  • the manufacturing processes for all dosage strength formulations are the same.
  • the manufacturing process can include preparing one or more pre-blends which are combined to form a final blend and subsequently forming final unit dosage forms.
  • the process can optionally include several techniques to facilitate formation of blends and batches of finished drug product with homogeneous distribution of drug substance and colorants including, for example: (1) de-agglomerating ingredients prior to blending; and/or (2) layering the drug substance and colorant components between additions of RxCIPIENTSTTM FM1000, Pharmaburst, or F-MeltTM, prior to mixing to create uniform pre-blends; and/or (3) serially diluting the drug substance and colorant pre-blends with RxCIPIENTSTTM FM1000, Pharmaburst, or F-MeltTM and other formulation excipients to create uniform final blends.
  • the process can optionally include, for example, (1) performing blend mixing time studies and assessing drug substance uniformity; and/or (2) optimizing the blend batch size with respect to the effective working capacity of the blenders.
  • Efficient mixing and acceptable blend and content uniformity can be difficult to obtain for low dose dosage forms.
  • the choice of blenders and the configuration of the storage container to tablet press powder transfer chute are selected based on optimization and maintenance of content uniformity.
  • excipients and process parameters can be selected to optimize main compression force and tablet press speed on the physical characteristics (hardness, friability, thickness and weight) of the finished dosage form.
  • the process can be optimized to compensate for the tendency for fluidization segregation of drug substance.
  • fluidization segregation can be reduced by eliminating process steps during which streams of air come in contact with the powder, for example, the step in the process when the blend is discharged from a V-blender into storage containers, and/or the step in the process when powder is fed from storage containers to the tablet press feed hopper.
  • the formulation is simple and contains few functional components.
  • the formulation can have excellent compression and flow properties and the tablet press can be operated at very high press speeds and this allows relatively manageable tablet press run times for even large batch sizes.
  • the direct compression manufacturing processes disclosed herein achieve a uniform distribution of drug substance in a low dose drug product without the need for complex wet or dry granulation manufacturing techniques.
  • the manufacturing process avoids costly techniques, such as those requiring large capital equipment investments, long manufacturing cycle times and associated low throughput.
  • the manufacturing process is designed to achieve a uniform blend by using; multiple blending steps, a specific order of addition in the blenders and screening steps to facilitate effective dispersion of the drug substance and excipients.
  • a screening step can be introduced to prevent agglomerates of drug substance from being carried over to subsequent manufacturing steps.
  • the manufacturing process is designed to maintain the uniform blend through to tableting via minimizing the transfer steps, for example, by using an in-bin blender to form the final blend and for example via use of a vented and valved transfer chute to the tablet press.
  • Embodiments relate to methods for improving sleep in a patient in need thereof, for example by administering low-dose doxepin, or a low-dose doxepin-related compound, in a tablet formulation as described herein.
  • the term “administer” and its variants contemplate both self-administration (by the patient) and administration by a third party.
  • the oral pharmaceutical as RxCIPIENTSTM FM1000, Pharmaburst, or F-MeltTM-containing doxepin formulations described herein are administered orally.
  • the methods described herein can be used to treat individuals suffering from a sleep disorder, such as insomnia.
  • the individual can suffer from a chronic insomnia or a non-chronic insomnia.
  • chronic insomnia or non-chronic insomnias a patient may suffer from difficulties in sleep onset, sleep maintenance (interruption of sleep during the night by periods of wakefulness), sleep duration, sleep efficiency, premature early-morning awakening, or a combination thereof.
  • the insomnia may be attributable to the concurrent use of other medication, for example.
  • the non-chronic insomnia can be, for example, a short term insomnia or a transient insomnia.
  • the chronic or non-chronic insomnia can be a primary insomnia or an insomnia that is secondary or attributable to another condition, for example a disease such as depression or chronic fatigue syndrome.
  • the patient can be one that is not suffering from an insomnia that is a component of a disease, or a patient can be treated that is otherwise healthy.
  • the chronic or non-chronic insomnia can be a primary insomnia, that is, one that is not attributable to another mental disorder, a general medical condition, or a substance.
  • such conditions may be associated with a chronic insomnia and can include, but are not limited to, insomnia attributable to a diagnosable DSM-IV disorder, a disorder such as anxiety or depression, or a disturbance of the physiological sleep-wake system.
  • the insomnia can be non-chronic, or of short duration (e.g., less than 3-4 weeks).
  • causes of such insomnia may be extrinsic or intrinsic and include, but are not limited to environmental sleep disorders as defined by the International Classification of Sleep Disorders (ICSD) such as inadequate sleep hygiene, altitude insomnia or adjustment sleep disorder (e.g., bereavement).
  • SSD International Classification of Sleep Disorders
  • short-term insomnia may also be caused by disturbances such as shift-work sleep disorder.
  • the methods can specifically exclude one or more of any of the sleep disorders described in the previous paragraph or elsewhere herein.
  • the methods can specifically exclude treating a chronic insomnia.
  • the methods can specifically exclude treating an insomnia that is attributable to a condition such as depression, anxiety or chronic fatigue.
  • the methods can include treating onset, duration, and maintenance aspects of insomnia in a patient.
  • the pharmaceutical tablet formulations disclosed herein have surprising efficacy, even in low doses, and also can allow a full 7 or 8 hours of sleep, or more, without significant next-day sedation. It is believed that these formulations are safe, provide rapid sleep onset, maintains sleep throughout the night for a full 7 or 8 hour sleep cycle, and allow normal activity the next day without hangover or unsafe levels of sedation.
  • doxepin plasma concentration achieved approximately 1 hour after a 3 mg dose is sufficient for sleep initiation.
  • doxepin plasma concentrations of 0.1 ng/mL or greater were associated with initiation of sleep.
  • the formulations of the present disclosure can provide rapid rise in plasma concentrations following administration, e.g., achieving a therapeutically effective plasma concentration of doxepin following a 3 mg dose in 60 minutes or less, for example, within 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 20 minutes, or less. Accordingly, some embodiments relate to formulations and dosage forms that result in more rapid achievement of effective plasma concentrations of doxepin leading to more rapid drug onset (e.g., sleep onset) at the dosages described herein, including, for example, dosages of 1 mg, 3 mg or 6 mg.
  • FIG. 1 shows the concentration of doxepin in the blood plasma over two hours. The concentration of doxepin in the first 30 minutes of the simulation was increased above 0.1 ng/mL in the blood plasma due to oral transmucosal absorption.
  • the blending process can include preparation of a drug substance pre-blend created by layering doxepin HCl between additions of quick dissolve excipient, followed by mixing.
  • the uniformity of unit dose potency can be further promoted by serially diluting and mixing the drug substance pre-blend with the remaining excipient(s).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US12/301,223 2006-05-19 2007-05-18 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia Abandoned US20110318412A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/301,223 US20110318412A1 (en) 2006-05-19 2007-05-18 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80182406P 2006-05-19 2006-05-19
US80182306P 2006-05-19 2006-05-19
US83331906P 2006-07-25 2006-07-25
PCT/US2007/012107 WO2007142811A2 (fr) 2006-05-19 2007-05-18 Formulations de doxépine à faible dose, incluant des formulations buccales, sublinguales et à dissolution rapide, et leurs utilisations pour traiter l'insomnie
US12/301,223 US20110318412A1 (en) 2006-05-19 2007-05-18 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012107 A-371-Of-International WO2007142811A2 (fr) 2006-05-19 2007-05-18 Formulations de doxépine à faible dose, incluant des formulations buccales, sublinguales et à dissolution rapide, et leurs utilisations pour traiter l'insomnie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/686,113 Continuation US20200078295A1 (en) 2006-05-19 2019-11-16 Low Dose Doxepin Formulations, Including Buccal, Sublingual And Fastmelt Formulations, And Uses Of The Same To Treat Insomnia

Publications (1)

Publication Number Publication Date
US20110318412A1 true US20110318412A1 (en) 2011-12-29

Family

ID=38801963

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/301,223 Abandoned US20110318412A1 (en) 2006-05-19 2007-05-18 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
US16/686,113 Pending US20200078295A1 (en) 2006-05-19 2019-11-16 Low Dose Doxepin Formulations, Including Buccal, Sublingual And Fastmelt Formulations, And Uses Of The Same To Treat Insomnia

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/686,113 Pending US20200078295A1 (en) 2006-05-19 2019-11-16 Low Dose Doxepin Formulations, Including Buccal, Sublingual And Fastmelt Formulations, And Uses Of The Same To Treat Insomnia

Country Status (5)

Country Link
US (2) US20110318412A1 (fr)
EP (1) EP2026792A2 (fr)
JP (1) JP2009537554A (fr)
CA (1) CA2687124A1 (fr)
WO (1) WO2007142811A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281990A1 (en) * 2006-05-19 2007-12-06 Rogowski Roberta L Methods of using low-dose doxepin for the improvement of sleep
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20090074862A1 (en) * 2007-04-13 2009-03-19 Luigi Schioppi Low-dose doxepin formulations and methods of making and using the same
US20100105614A1 (en) * 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179214A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100227916A1 (en) * 2006-05-19 2010-09-09 Somaxon Pharmaceuticals, Inc N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US20110166215A1 (en) * 2006-07-20 2011-07-07 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US11179330B2 (en) 2019-12-23 2021-11-23 Xiamen Lp Pharmaceutical Co., Ltd. Doxepin oral transmucosal film
US11234954B2 (en) 2006-05-19 2022-02-01 Currax Pharmaceuticals Llc Low-dose doxepin for treatment of sleep disorders in elderly patients

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510345A (ja) * 2014-02-07 2016-04-07 サイラブス， ファーマシューティカルズ 全自然非毒性舌下薬剤の送達システム
US11096896B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
US5502047A (en) * 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
US6211229B1 (en) * 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
WO2001039749A2 (fr) * 1999-11-30 2001-06-07 Panacea Biotec Limited Composition a dissolution rapide et a gout sucre de longue duree
US20030175355A1 (en) * 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
US20050226925A1 (en) * 2004-02-17 2005-10-13 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2406299A (en) * 1998-02-12 1999-08-30 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
CA2461044A1 (fr) * 2001-09-26 2003-04-03 Pharmacia Corporation Compositions de valdecoxib se desintegrant dans la bouche
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
NZ534340A (en) * 2002-02-07 2006-04-28 Pharmacia Corp Pharmaceutical dosage form for mucosal delivery
CN1562013A (zh) * 2004-03-31 2005-01-12 江西天施康中药股份有限公司 用于治疗高血压病的尼索地平口腔崩解片及制备方法
WO2005102335A2 (fr) * 2004-04-23 2005-11-03 Hypnion, Inc. Methodes de traitement de troubles du sommeil

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
US5502047A (en) * 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
WO2001039749A2 (fr) * 1999-11-30 2001-06-07 Panacea Biotec Limited Composition a dissolution rapide et a gout sucre de longue duree
US6211229B1 (en) * 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
US20030175355A1 (en) * 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20050226925A1 (en) * 2004-02-17 2005-10-13 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238620B2 (en) 2006-05-19 2019-03-26 Pernix Sleep, Inc. Methods of using low-dose doxepin for the improvement of sleep
US10251859B2 (en) 2006-05-19 2019-04-09 Pernix Sleep, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US9498462B2 (en) 2006-05-19 2016-11-22 Pernix Sleep, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US11234954B2 (en) 2006-05-19 2022-02-01 Currax Pharmaceuticals Llc Low-dose doxepin for treatment of sleep disorders in elderly patients
US20070281990A1 (en) * 2006-05-19 2007-12-06 Rogowski Roberta L Methods of using low-dose doxepin for the improvement of sleep
US20100179214A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100227916A1 (en) * 2006-05-19 2010-09-09 Somaxon Pharmaceuticals, Inc N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US10143676B2 (en) 2006-05-19 2018-12-04 Pernix Sleep, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US9861607B2 (en) 2006-05-19 2018-01-09 Procom One, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20110178166A1 (en) * 2006-05-19 2011-07-21 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US8513299B2 (en) 2006-05-19 2013-08-20 Pernix Sleep, Inc. Methods of using low-dose doxepin for the improvement of sleep
US9107898B2 (en) 2006-05-19 2015-08-18 Pernix Sleep, Inc. Methods of using low-dose doxepin for the improvement of sleep
US9463181B2 (en) 2006-05-19 2016-10-11 Pemix Sleep, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US9486437B2 (en) 2006-05-19 2016-11-08 Pernix Sleep, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US10653660B2 (en) 2006-07-20 2020-05-19 Currax Pharmaceuticals Llc Methods of improving the pharmacokinetics of doxepin
US9572814B2 (en) 2006-07-20 2017-02-21 Pernix Sleep, Inc. Methods of improving the pharmacokinetics of doxepin
US20110166215A1 (en) * 2006-07-20 2011-07-07 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US9907779B2 (en) 2006-10-25 2018-03-06 Pernix Sleep, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US10507193B2 (en) 2006-10-25 2019-12-17 Currax Pharmaceuticals Llc Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20100105614A1 (en) * 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US11013712B2 (en) 2006-12-06 2021-05-25 Currax Pharmaceuticals Llc Methods of treating insomnia using a combination therapy of low-dose doxepin and zolpidem
US20090074862A1 (en) * 2007-04-13 2009-03-19 Luigi Schioppi Low-dose doxepin formulations and methods of making and using the same
US9532971B2 (en) 2007-04-13 2017-01-03 Pernix Sleep, Inc. Low-dose doxepin formulations and methods of making and using the same
US9907780B2 (en) 2007-04-13 2018-03-06 Pernix Sleep, Inc. Low-dose doxepin formulations and methods of making and using the same
US11096920B2 (en) 2007-04-13 2021-08-24 Currax Pharmaceuticals Llc Low-dose doxepin formulations and methods of making and using the same
US11179330B2 (en) 2019-12-23 2021-11-23 Xiamen Lp Pharmaceutical Co., Ltd. Doxepin oral transmucosal film

Also Published As

Publication number Publication date
US20200078295A1 (en) 2020-03-12
EP2026792A2 (fr) 2009-02-25
CA2687124A1 (fr) 2007-12-13
WO2007142811A3 (fr) 2008-03-13
WO2007142811A2 (fr) 2007-12-13
JP2009537554A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
US20200078295A1 (en) Low Dose Doxepin Formulations, Including Buccal, Sublingual And Fastmelt Formulations, And Uses Of The Same To Treat Insomnia
US11096920B2 (en) Low-dose doxepin formulations and methods of making and using the same
TWI387465B (zh) 具有改良之藥物動力學性質之藥物配製物
KR101819903B1 (ko) 구강 삽입용 투여 제형
KR20190015597A (ko) 설하 필름
CN1317309A (zh) 快速溶化口服药物制剂
US8252809B2 (en) Compositions for treating insomnia
US20110046115A1 (en) Mirtazapine Solid Dosage Forms
US20100249178A1 (en) Compositions and methods for treating middle-of-the-night insomnia
JP2003034655A (ja) 速崩壊性固形製剤
JP4944467B2 (ja) 医薬用組成物
TW202211909A (zh) 超高速崩解錠劑及其製造方法
Awad et al. Fast-disintegrating tablets: a novel approach in pharmaceutical preparation
US20110038928A1 (en) Orally disintegrating tablets of zolmitriptan
US20130143912A1 (en) Sublingual zolpidem formulations
JP5148801B2 (ja) 催眠用固形製剤
JP2010053048A (ja) 苦味が緩和されたイルベサルタン含有医薬組成物
JP2024536341A (ja) 自閉症スペクトラム障害を有する対象を治療するための方法及び製品
WO2024047352A1 (fr) Composition pharmaceutique orodispersible de fexofénadine et son procédé de préparation
CN117750956A (zh) 用于治疗抑郁状态的方法
WO2016015797A1 (fr) Mini-comprimés dispersibles dans l'eau comprenant de l'énalapril utilisés dans le traitement de l'hypertension dans une population pédiatrique et procédé de préparation desdits mini-comprimés

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROCOM ONE, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAVEY, NEIL B.;COBB, TERRY;SIGNING DATES FROM 20100430 TO 20100506;REEL/FRAME:024366/0045

AS Assignment

Owner name: SOMAXON PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHIOPPI, LUIGI;DORSEY, BRIAN;SKINNER, MICHAEL;AND OTHERS;SIGNING DATES FROM 20100324 TO 20100409;REEL/FRAME:026441/0070

AS Assignment

Owner name: MIDCAP FINANCIAL, LLC, MARYLAND

Free format text: SECURITY AGREEMENT;ASSIGNOR:PERNIX SLEEP, INC.;REEL/FRAME:030441/0229

Effective date: 20130508

AS Assignment

Owner name: MIDCAP FINANCIAL, LLC, MARYLAND

Free format text: PATENT TRANSFER AND ASSIGNMENT;ASSIGNOR:MIDCAP FUNDING V, LLC;REEL/FRAME:031266/0437

Effective date: 20130508

Owner name: MIDCAP FUNDING IV, LLC, MARYLAND

Free format text: PATENT TRANSFER AND ASSIGNMENT;ASSIGNOR:MIDCAP FINANCIAL, LLC;REEL/FRAME:031266/0572

Effective date: 20130616

AS Assignment

Owner name: PERNIX THERAPEUTICS HOLDINGS, INC., TEXAS

Free format text: MERGER;ASSIGNOR:SOMAXON PHARMACEUTICALS, INC.;REEL/FRAME:032118/0272

Effective date: 20130306

AS Assignment

Owner name: PERNIX SLEEP, INC., MISSISSIPPI

Free format text: RELEASE OF SECURITY INTEREST IN PATENT RIGHTS REEL/FRAME 030441/0229;ASSIGNOR:MIDCAP FUNDING IV, LLC (SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL, LLC);REEL/FRAME:032330/0023

Effective date: 20140221

AS Assignment

Owner name: PERNIX SLEEP, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERNIX THERAPEUTICS HOLDINGS, INC.;REEL/FRAME:036387/0667

Effective date: 20150819

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: CURRAX PHARMACEUTICALS LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERNIX SLEEP, INC.;REEL/FRAME:049329/0730

Effective date: 20190425

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION